We interpreted these results to indicate that both the expression level and intensity of MUC16 on the surface of tumor cells was crucial considerations when design an effective MUC16 CAR T cell therapy, such that ovarian cancer cells that expressed low levels of cell-surface MUC16 might not be efficiently targeted by targeting CAR T cells for elimination. The gene discussed is MUC16; the disease is neoplasm.